Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.69 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.69 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.69 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.69 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2575867 | 1.00 | HDAC1 (0.69) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL27187341 | 0.87 | HDAC1 (0.71) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL27187307 | 0.81 | HDAC2 (1.00) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL31324246 | 0.79 | HDAC2 (0.45) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL1124089 | 0.79 | HDAC1 (0.52) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL1124090 | 0.79 | HDAC1 (0.52) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL2577800 | 0.79 | HDAC1 (0.66) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL2577796 | 0.79 | HDAC1 (0.66) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL5520909 | 0.75 | HDAC1 (0.41) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL7186157 | 0.75 | HDAC1 (0.41) | HDAC1HDAC2HDAC3HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025030117-A1 | FERROPTOSIS INDUCERS | ARPEGGIO BIOSCIENCES, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| US-20240109852-A1 | Ferroptosis-HDAC Inhibitor Hybrid Anticancer Agents | THE UNIVERSITY OF TOLEDO (US) | 2024-04-04 | — | — | US | disclosed |
| EP-4308570-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022194976-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-09-22 | — | — | WO | disclosed |
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20210179603-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-17 | — | — | US | disclosed |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2021-06-17 | — | — | US | disclosed |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-17 | — | — | US | disclosed |
| EP-2089397-B1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL]-2-PHENYL-5H-THIAZ0L0 [5,4-C]PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8049013-B2 | 5- [4-(azetidin-3-yloxy)-phenyl]-2-phenyl-5H-thiazolo[5,4-C] pyridin-4-one derivatives and their use as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| US-8049013-B2 | 5- [4-(azetidin-3-yloxy)-phenyl]-2-phenyl-5H-thiazolo[5,4-C] pyridin-4-one derivatives and their use as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| US-8049013-B2 | 5- [4-(azetidin-3-yloxy)-phenyl]-2-phenyl-5H-thiazolo[5,4-C] pyridin-4-one derivatives and their use as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| US-20100069352-A1 | 5- [4-(AZETIDIN-3-YLOXY)-PHENYL]-2-PHENYL-5H-THIAZOLO[5,4-C] PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20100069352-A1 | 5- [4-(AZETIDIN-3-YLOXY)-PHENYL]-2-PHENYL-5H-THIAZOLO[5,4-C] PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20100069352-A1 | 5- [4-(AZETIDIN-3-YLOXY)-PHENYL]-2-PHENYL-5H-THIAZOLO[5,4-C] PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
| EP-2089397-A1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL]-2-PHENYL-5H-THIAZ0L0 [5,4-C]PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008076562-A1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL] -2-PHENYL-5H-THIAZ0L0 [5,4-C] PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076562-A1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL] -2-PHENYL-5H-THIAZ0L0 [5,4-C] PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | HDAC1 226/4885HDAC2 530/4885HDAC3 1252/4885 |
| US-20210179603-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | HDAC1 226/4885HDAC2 530/4885HDAC3 1252/4885 |
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PARK7, PINK1 | HDAC1 1077/4885HDAC2 1193/4885HDAC3 1830/4885 |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | HDAC1 502/4885HDAC2 299/4885HDAC3 549/4885 |
| US-20100069352-A1 | 5- [4-(AZETIDIN-3-YLOXY)-PHENYL]-2-PHENYL-5H-THIAZOLO[5,4-C] PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, HCRTR1 | HDAC1 1601/4885HDAC2 2596/4885HDAC3 499/4885 |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | KDM1A, KDM1B, KDM2A | HDAC1 226/4885HDAC2 530/4885HDAC3 1252/4885 |
| US-20240109852-A1 | Ferroptosis-HDAC Inhibitor Hybrid Anticancer Agents | AIFM2, HDAC11, HDAC8 | HDAC1 4/4885HDAC2 6/4885HDAC3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.